| Entry |
|
|---|
| Name |
Amplified ERBB2 to PI3K signaling pathway
|
|---|
| Definition |
EGF -> (ERBB2*+EGFR) -> PI3K -> PIP3 -> AKT -> MTOR -> S6K |
|---|
| Expanded |
1950 -> (2064v3+1956) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475 -> (6198,6199) |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
|
|---|
| Gene |
| 1950 | EGF; epidermal growth factor |
| 2064 | ERBB2; erb-b2 receptor tyrosine kinase 2 |
| 1956 | EGFR; epidermal growth factor receptor |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 2475 | MTOR; mechanistic target of rapamycin kinase |
| 6198 | RPS6KB1; ribosomal protein S6 kinase B1 |
| 6199 | RPS6KB2; ribosomal protein S6 kinase B2 |
|
|---|
| Variant |
2064v3 (ERBB2*) ERBB2 amplification
|
|---|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
|---|
| Reference |
|
|---|
| Authors |
Ciardiello F, Tortora G |
|---|
| Title |
EGFR antagonists in cancer treatment. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Riquelme I, Saavedra K, Espinoza JA, Weber H, Garcia P, Nervi B, Garrido M, Corvalan AH, Roa JC, Bizama C |
|---|
| Title |
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA |
|---|
| Title |
Gastric cancer-molecular and clinical dimensions. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Bertotti A, Sassi F |
|---|
| Title |
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
